Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, shared on LinkedIn:
“A 1-centimeter tumor on a standard scan isn’t an early biological event. It’s an established metropolis of roughly one billion cells-clonally diverse, vascularized, and primed for treatment resistance.
Today, emerging multiomic tools and high-dimensional classifiers are beginning to spot malignant signals at roughly 100,000 cells.
Yet when a patient has confirmed molecular activity with negative imaging, our 20th-century screening guidelines offer only one recourse: watchful waiting. In practice, that means sending the patient home until the tumor grows large enough to see, biopsy, and cut. Imagine intercepting intelligence that an adversary is pitching camp in an open field, but ordering your troops to wait until they finish building stone ramparts and mounting artillery-simply because the manual only explains how to run a siege.
We need to start preparing our diagnostic and clinical frameworks for the ‘Pre-Patient’ and Molecular-Only Disease (MOD).
What if early-stage interception-using targeted therapies, neoantigen mRNA vaccines, or short-course immunotherapies-could clear these fragile, pre-angiogenic cells before they ever establish a blood supply?
The science isn’t fully ready today, but it may be in 2–3 years. We don’t have to abandon academic rigor to question whether 15-year static trial designs are fit for purpose in an era of iterative molecular diagnostics. I laid out the arithmetic, the biology of scale, and the policy bottlenecks in my latest piece.
How should oncology adapt its evidentiary standards as detection shifts from anatomy to molecular systems?“